Current Issues of Pharmacy and Medical Sciences

Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome

Curr Issues Pharm Med Sci., Vol. 30, No. 3,

Olesya Olha Horbatiuk1*, Alla Binkovska1, Olena Herych1, Andriy Ropotan2,
Natalia Zhylko2, Iryna Mandziy2, Iryna Buleza2

Department of Obstetrics and Gynecology, Faculty of Postgraduate Education, National Pirogov Memorial Medical University, 29000 Vodoprovidna 8/1, Khmelnytsky, Ukraine
2 City Prenatal Center, Khmelnytsky, Ukraine



In this study, we carried out the clinical and laboratory research of severe PMS (premenstrual syndrome) treatment in premenopausal age women. Herein, 37 women were examined and observed before the beginning of treatment and three months after it. Medication containing micronized progesterone was used for treatment (sublingually, 100 mg from 11 to 25 days of menstrual cycle). After three months of micronized progesterone treatment, 86.5% of all women-participants of the study were observed to have full regression of clinical symptoms, while 13.5% of all patients were observed to have decrease in clinical symptoms of severe PMS. Moreover, hormonal research results revealed significant (1.3 times) decrease in LH (Luteinizing hormone) level and (1.3 times) increase in progesterone level after three months of treatment (р<0.05). The high bio-accessibility of the medication and its natural structure made it possible to decrease the dose and avoid risks of hepatotoxicity.

Full text


PMS; treatment; per menopause; micronized progesterone


July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31